A review of the presentation by Sabine Tejpar. The KRAS (codon 12,13) is a validated predictive biomarker in mCRC, it is essential to determine diagnosis and required prior… read more.
A review of the presentation by Volker Heinemann (pictured). The decision on first line treatment in mCRC matters because the number of patients benefitting from therapy diminishes with… read more.
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
We ask Professor Heinz-Josef Lenz, Professor of Medicine, Associate Director Clinical Research what he thinks is going to be the next big thing in colorectal cancer for the… read more.
Accurate, robust and simple method of identification has potential benefits to patients, hospitals and health services around the world.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
The use of a smartphone application significantly improves patients’ preparation for a colonoscopy, according to new research. The preparation process, which begins days in advance of the procedure,… read more.
Colon cancer develops slowly. Precancerous lesions usually need many years to turn into a dangerous carcinoma. They are well detectable in an endoscopic examination of the colon called… read more.
Taken from the New England Journal of Medicine (NEJM) – by Bruce Sylvester – Ustekinumab, a drug used to treat psoriasis, appears to decrease the debilitating effects of… read more.
Taken from the New England Journal of Medicine (NEJM) – by Bruce Sylvester – Ustekinumab, a drug used to treat psoriasis, appears to decrease the debilitating effects of… read more.
by Gary Finnegan – Emerging uses of EMA Approved Drugs – The EMA has given the green light for the first medicine specifically for irritable bowel syndrome (IBS)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
